Clinical Trials List
2022-07-01 - 2031-04-21
Phase I/II
Recruiting6
ICD-10C18.3
Malignant neoplasm of hepatic flexure
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9153.0
Malignant neoplasm of hepatic flexure colon
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 林建良 Division of Hematology & Oncology
- 高婉真 Division of Hematology & Oncology
- 曹朝榮 Division of Hematology & Oncology
- 陳昭勳 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 黃文聰 Division of Hematology & Oncology
- Shang-Wen Chen Division of Hematology & Oncology
- 陳威宇 未分科
- 林正耀 Division of Hematology & Oncology
- 蕭聖諺 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張境夫 Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- 余紹銘 Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shang-Hung Chen 未分科
- Po-Wen Lin 未分科
- 黃盈慈 未分科
- 陳柏全 未分科
- Peng-Chan Lin 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
230 participants
